Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

• PRE REGISTRATION ? INCLUSION CRITERIA: Ability to understand and the willingness to sign a written informed consent document
• PRE REGISTRATION ? INCLUSION CRITERIA: Patient has disease amenable to biopsy if the archival tissue sample is unavailable; note: Archive sample must not be older than 12 months
• REGISTRATION ? INCLUSION CRITERIA
• Phase I only: Diagnosis of advanced/metastatic NSCLC for which no standard treatment option; Phase II only: Advanced NSCLC patients who have received at least 1 platinum-based systemic chemotherapy regimen
• Patients with tumors having actionable genomic alterations should have received prior therapy with Food and Drug Administration (FDA) approved agents targeting these aberrations (ie EGFR, ALK, ROS1, BRAF V600E)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Phase II only: Must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• Ability to understand and the willingness to sign a written informed consent document
• Histological or cytologically confirmed NSCLC that shows moderate or stronger mesothelin expression in 30% of tumor cells by a companion assay; MSLN expression score using Ventana immunohistochemistry (IHC) SP74 assay; Phase I only: In addition 5- 30% tumor cells and 1, 2, or 3+ MSLN score; Phase II only: 30% tumor cells and either 2+/3+
• Life expectancy of \>= 12 weeks
• Absolute neutrophil count \>= 1.5 ? 10\^9/L =\< 14 days prior to registration
• Platelets \>= 100 ? 10\^9/L =\< 14 days prior to registration
• Hemoglobin \>= 9 g/dL =\< 14 days prior to registration
• Potassium \>= lower limit of normal (LLN) range for the institution =\< 14 days prior to registration
• NOTE: Supplementation may be given before the first dose of study medication
• Calcium \>= LLN (corrected for serum albumin, if albumin abnormal) =\< 14 days prior to registration
• NOTE: Supplementation may be given before the first dose of study medication
• Magnesium \>= LLN =\< 14 days prior to registration
• NOTE: Supplementation may be given before the first dose of study medication
• Sodium \>= LLN =\< 14 days prior to registration
• NOTE: Supplementation may be given before the first dose of study medication
• Phosphorus \>= LLN =\< 14 days prior to registration
• NOTE: Supplementation may be given before the first dose of study medication
• International normalized ratio (INR) =\< 1.5 =\< 14 days prior to registration
• Serum creatinine =\< 1.5 mg/dL or creatinine clearance \>= 50 mL/min (calculated by Cockcroft Gault equation) =\< 14 days prior to registration
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN or =\< 5 x upper limits of normal (ULN) if liver metastases are present =\< 14 days prior to registration
• Total bilirubin =\< 1.5 x ULN =\< 14 days prior to registration
• Standard 12-lead electrocardiogram (ECG) with the following parameters at screening (defined as the mean of the triplicate ECGs):
• QT corrected by Fridericia's formula (QTcF) interval at screening \< 450msec (using Fridericia?s correction)
• Negative pregnancy test performed =\< 7 days prior to registration (women of childbearing potential only)
• Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
• Willing to provide blood samples for correlative research purposes

REGISTRATION ?